Doryx Mpc (Doxycycline Hyclate) Patent Expiration, LOE Window & CMS Spending
Doryx Mpc (Doxycycline Hyclate) by Mayne International Pty: FDA Orange Book LOE 2034-12-23, 4 AB generics, $1.3M 2024 CMS Part D & Medicaid spend, and $1,200 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Mayne International Pty |
| FDA Application & Pathway | N050795 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2034-12-23 |
| Orange Book Patents (*PED Extensions) | 4 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 4 |
| 2024 CMS Total Public Spend | $1.3M |
| 2024 Medicare Part D Spend | $244K |
| 2024 Medicaid Spend | $1.1M |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($1,200 intro WAC) |